GlassScriptPhysician profile
Stephen K Keith
NPI 1376878926
$9,906.89
in general payments reported to CMS, 2019-2025
37 companies · $2,068 in 2025
The $2,068 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,552 · 2022: $2,177 · 2023: $2,021 · 2024: $2,089 · 2025: $2,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,133 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,132.77 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,797.48 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,615.31 | 2021-2025 | |
| Lilly USA, LLC | $1,317.49 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $704.00 | 2021-2025 | |
| Glaxosmithkline, LLC. | $679.96 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $445.67 | 2021-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $407.49 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $257.71 | 2021-2025 | Gardasil 9, Capvaxive |
| Mylan Specialty L.P. | $252.87 | 2021-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.86 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $205.23 | 2021-2024 | Xarelto, Spravato |
| Sanofi-Aventis U.S. LLC | $196.33 | 2021-2023 | |
| Amarin Pharma, INC. | $187.74 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $143.09 | 2022-2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.96 | 2021-2025 | Xifaxan |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $111.31 | 2021-2023 | |
| Corcept Therapeutics | $109.30 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $101.76 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $98.52 | 2024-2025 | |
| Abbott Laboratories | $92.34 | 2021-2025 | Freestyle Libre 3 |
| Allergan, INC. | $91.67 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $83.23 | 2023-2024 | Eliquis, Camzyos |
| Exact Sciences Corporation | $78.64 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $78.54 | 2024-2025 | Watchman Flx, Watchman Access System |
| Takeda Pharmaceuticals U.S.A., INC. | $74.11 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $64.24 | 2023-2024 | Rexulti, Nuedexta |
| Kowa Pharmaceuticals America, INC. | $52.31 | 2021 | |
| Eisai INC. | $47.05 | 2021 | |
| Nevro Corp. | $46.34 | 2022 | |
| Astellas Pharma US INC | $33.57 | 2023-2024 | Veozah |
| Vifor Pharma, INC. | $29.28 | 2022 | |
| Esperion Therapeutics, INC. | $29.18 | 2021 | |
| Genentech USA, INC. | $23.71 | 2021-2022 | |
| Optinose US, INC. | $21.30 | 2024 | |
| Almatica Pharma LLC | $20.74 | 2022 | |
| Ibsa Pharma INC. | $15.27 | 2021 | |
| Currax Pharmaceuticals LLC | $14.29 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Keith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.